Mutations in tumor signaling, metastases, and synthetic lethality establish distinct patterns

Area of Science:

• Oncology
• Genomics
• Computational Biology

Background:

• Accurate identification of oncogenic mutations is critical for cancer diagnosis, treatment selection, and predicting patient outcomes.
• Understanding mutation co-occurrence and exclusion patterns can elucidate mechanisms of oncogene-induced senescence and inform therapeutic strategies.

Purpose of the Study:

• To develop a novel computational framework for discovering co-existing and excluded oncogenic mutations within oncoproteins.
• To map identified mutations onto biological pathways to guide combinatorial drug selection and identify metastasis markers.
• To investigate the molecular basis of synthetic lethality in cancer.

Main Methods:

• Analysis of approximately 60,000 pan-cancer tumor sequences.
• Development of a computational framework to detect tumor-specific co-existing mutations.
• Mapping identified mutations onto signaling pathways.

Main Results:

• Identification of 3424 co-existing tumor-specific mutations across the analyzed cohort.
• Demonstration that co-existing mutations preferentially promote specific primary tumors.
• Discovery of novel mutations associated with metastasis, including specific markers for metastatic breast cancer.

Conclusions:

• The developed framework clarifies the mechanistic basis of intratumor mutational diversity.
• The study provides valuable genomic markers for detecting metastasis and guides the development of metastasis-targeting therapies.
• Pathway mapping of mutations offers a resource for optimizing drug combinations in cancer treatment.